Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization

Redox Biology

Volumn 2, Issue 1, 2014, Pages 485-494

  Li, Y ^a,b   Liu, X ^a   Zhou, T ^a   Kelley, M R ^c   Edwards, P ^a   Gao, H ^a   Qiao, X ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; APE1 Ref 1redox function; E3330; Oxidative stress; Retinal pigment epithelial cell; Transcription factor

Indexed keywords

ANTIOXIDANT; E 3330; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; REDOX EFFECTOR FACTOR 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN; APEX1 PROTEIN, HUMAN; BENZOQUINONE DERIVATIVE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; NEUROPROTECTIVE AGENT; PROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BRUCH MEMBRANE; CELL AGING; CELL LEVEL; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN CELL; LETHAL DOSE; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY;

ANIMALS; BENZOQUINONES; CELL AGING; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; GENE EXPRESSION REGULATION; HUMANS; INTRAVITREAL INJECTIONS; MICE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROPIONATES; RETINAL PIGMENT EPITHELIUM;

EID: 84895419993     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.01.023     Document Type: Article

References (80)

1. Tomany SC W.J., Van Leeuwen R., Klein R., Mitchell P., Vingerling J.R., Klein B.E., Smith W., De Jong P.T. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004, 111:1280-1287.
2. Ryskulova A.T.K., Makuc D.M., Cotch M.F., Klein R.J., Janiszewski R. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 national health interview survey. Am. J. Public Health 2008, 98:454-461.
3. Ferris FL F.S., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984, 102:1640-1642.
4. Brown DM M.M., Kaiser P.K., Heier J.S., Sy J.P., Ianchulev T. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009, 116:57-65.e55.
5. CATT Research Group, M.D., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., Jaffe G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011, 364:1897-1908.
6. Tufail A.P.P., Egan C., Hykin P., da Cruz L., Gregor Z., Dowler J., Majid M.A., Bailey C., Mohamed Q., Johnston R., Bunce C., Xing W. ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. Br. Med. J. 2010, 340. 10.1136/bmj.c2459.
7. WR G. Histopathology of age-related macular degeneration. Mol. Vis. 1999, 27.
8. JG.H. Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest. Ophthalmol. Vis. Sci. 2010, 51:1275-1281.
9. Fishel ML K.M. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Asp. Med. 2007, 28:375-395.
10. Luo M D.S., Jiang A., Reed A., He Y., Fishel M., Nyland R.L.2nd, Borch R.F., Qiao X., Georgiadis M.M., Kelley M.R. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid. Redox Signal 2008, 10:1853-1867.
11. Tell G Q.F., Tiribelli C., Kelley M.R. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox Signal 2009, 11:601-620.
12. Bhakat KK M.A., Mitra S. Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid. Redox Signal 2009, 11:621-638.
13. Evans AR L.-F.M., Kelley M.R. Going APE over ref-1. Mutat. Res. 2000, 461:83-108.
14. Wilson DM B.D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat. Res. 2001, 485:283-307.
15. Tell G D.G., Caldwell D., Kelley M.R. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxid. Redox Signal 2005, 7:367-384.
16. Kelley M.R.G.M., Fishel M.L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr. Mol. Pharmacol. 2012, 5:36-53.
17. Ando K H.S., Kabe Y., Ogura Y., Sato I., Yamaguchi Y., Wada T., Handa H. A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 2008, 36:4327-4336.
18. Zou GM K.C., Kabe Y., Handa H., Anders R.A., Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J. Cell. Physiol. 2009, 219:209-218.
19. Xanthoudakis S M.G., Wang F., Pan Y.C., Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J. 1992, 11:3323-3335.
20. Xanthoudakis S C.T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 1992, 11:653-665.
21. Jayaraman L M.K., Zhu C., Curran T., Xanthoudakis S., Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 1997, 11:558-570.
22. Xanthoudakis S M.G., Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:23-27.
23. Zhang J., Marasco L.M., Logsdon D., LaFavers D., Chen K.A., Reed Q., Kelley A., Gross M.R., Georgiadis MM.M.L. Inhibition of apurinic/apyrimidinic endonuclease I[U+05F3]s redox activity revisited. Biochemistry 2013, 52:2955-2966.
24. Shimizu N., Tang S.K., Nishi J., Sato T., Hiramoto I., Aizawa M., Hatakeyama S., Ohba M., Hatori R., Yoshikawa H., Suzuki T., Oomori F., Tanaka A., Kawaguchi H., Watanabe H., Handa H.H. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 2000, 18:877-881.
25. Hiramoto M., Sugimoto S.N., Tang K., Kawakami J., Ito Y., Aizawa M., Tanaka S., Makino H., Handa H.I. Nuclear targeted suppression of NF-κB activity by the novel quinone derivative E3330. J. Immunol. 1998, 160:810-819.
26. Nyland R.L., Kelley L.M., Borch RF.M.R. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). J. Med. Chem. 2010, 53:1200-1210.
27. Wang X.C., Allen J.C., Roberts J.B., Jaffe GJ.W.L. Suppression of NF-kappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest. Ophthalmol. Vis. Sci. 1999, 40:477-486.
28. Kaarniranta K S.A. NF-kappaB signaling as a putative target for omega-3 metabolites in the prevention of age-related macular degeneration (AMD). Exp. Gerontol. 2009, 44:685-688.
29. Arjamaa O., Salminen N.M., Kaarniranta K.A. Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD). Ageing Res. Rev. 2009, 8:349-358.
30. Jonas J.B., Neumaier T.Y., Findeisen P.M. Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch. Ophthalmol. 2010, 128:1281-1286.
31. Raoul W., Camelo A.C., Guillonneau S., Feumi X., Combadière C., Sennlaub F.C. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J. Neuroinflamm. 2010, 87.
32. Jiang A., Kelley G.H., Qiao X.M.R. Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vis. Res. 2011, 51:93-100.
33. Qiao X., Zhou L.Y., Liu T., Kelley X., Edwards M.R., Gao H.P. Selective blocking of APE1/Ref-1 redox function by a novel compound, APX3330 inhibits choroidal endothelial cells in vitro and choroidal neovascularization in vivo. Abstr. Assoc. Res. Vis. Ophthalmol. 2012, 342.
34. Yan T., C.M., Zacharek A., Ning R., Qiao X., Kelley M.R., Roberts C., Chen J., Neurorestorative therapy for stroke in type one diabetic rats using APX3330, JCBFM Meeting, 2013.
35. O.S. The retinal pigment epithelium in visual function. Physiol. Rev. 2005, 85:845-881.
36. Simó R., Corraliza V.M., Hernández L., Garcia-Ramírez M.C. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier - implications for the pathogenesis of diabetic retinopathy. J. Biomed. Biotechnol. 2010, 190724.
37. Roth F., Holz FG.B.A. Key pathophysiologic pathways in age-related macular disease. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:710-716.
38. Ruberti J.W., Millican C.C., Menco C.L., Huang B.P., Johnson M.J.D. Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch[U+05F3]s membrane. Invest. Ophthalmol. Vis. Sci. 2003, 44:1753-1759.
39. Mettu P.S., Ong W.A., Cousins SW.S.S. Retinal pigment epithelium response to oxidant injury in the pathogenesis of early age-related macular degeneration. Mol. Asp. Med. 2012, 33:376-398.
40. Yamada Y., Yang T.J., Cutler Y., Wu R.G., Telljohann T., Mattson R.S., Handa JT.M.P. Oxidized low density lipoproteins induce a pathologic response by retinal pigmented epithelial cells. J. Neurochem. 2008, 105:1187-1197.
41. Kim J.H., Kim L.S., Yu K.W., Kim JH.Y.S. Oxidized low density lipoprotein-induced senescence of retinal pigment epithelial cells is followed by outer blood-retinal barrier dysfunction. Int. J. Biochem. Cell Biol. 2012, 44:808-814.
42. M.R.K. RPE cell senescence: a key contributor to age-related macular degeneration. Med. Hypotheses 2012, 78:505-510.
43. Beatty S., Phil K.H., Henson M., Boulton M.D. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000, 45:115-134.
44. Penfold P.L., Gillies M.M., Provis JM.M.C. Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye Res. 2001, 20:385-414.
45. Witmer A.N., Van Noorden V.G., Schlingemann RO.C.J. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22:1-29.
46. Ishida B.Y., Duncan B.K., Chalkley K.G., Burlingame R.J., Kane A.L., Schwartz DM.J.P. Regulated expression of apolipoprotein E by human retinal pigment epithelial cells. J. Lipid Res. 2004, 45:263-271.
47. Johnson L.V., Banna F.D., Radeke C.D., Maloney C.M., Hu M.A., Spencer J., Walker C.N., Tsie A.M., Bok M.S., Radeke D., Anderson DH.M.J. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18277-18282.
48. Nishi T., Hiramoto S.N., Sato M., Yamaguchi I., Hasegawa Y., Aizawa M., Tanaka S., Kataoka H., Watanabe K., Handa H.H. Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J. Biol. Chem. 2002, 277:44548-44556.
49. Goto M., Katayama Y.K., Tanaka I.K. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B. Mol. Pharmacol. 1996, 49:860-873.
50. Fishel M.L., Rajeshkumar J.Y., Scandura N.V., Sinn G., He A.L., Shen Y., Jones C., Pollok D.R., Ivan K.E., Maitra M., Kelley M.R.A. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol. Cancer Ther. 2011, 10:1698-1708.
51. Han W., Cai L.H., Gleaves J., Polosukhin L.A., Segal V.V., Yull B.H., Blackwell TS.F.E. NADPH oxidase limits lipopolysaccharide-induced lung inflammation and injury in mice through reduction-oxidation regulation of NF-κB activity. J. Immunol. 2013, 190:4786-4794.
52. Chiarini L.B., Petrs-Silva F.F., Linden R.H. Evidence that the bifunctional redox factor / AP endonuclease Ref-1 is an anti-apoptotic protein associated with differentiation in the developing retina. Cell Death Differ. 2000, 7:272-281.
53. Chiarini LB L.R. Tissue biology of apoptosis. Ref-1 and cell differentiation in the developing retina. Ann. N. Y. Acad. Sci. 2000, 64-78.
54. Wu H.H., Chang C.Y., Wu J.T., Liu T.C., Chen W.S., Lee H.C.Y. Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene 2010, 29:4330-4340.
55. Xanthoudakis S., Wallace S.R., Curran T.J.D. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8919-8923.
56. Fishel M.L., Reed H.Y., Chin-Sinex A.M., Hutchins H., Mendonca G.D., Kelley M.R.M.S. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst.) 2008, 7:177-186.
57. Ono Y., Ohmoto F.T., Akiyama T., Seki S.K. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutat. Res. 1994, 315:55-63.
58. Walker L.J., Harris C.R., Hickson ID.A.L. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res. 1994, 22:4884-4889.
59. Jiang Y., Sandusky Z.S., Kelley G.E., Fishel ML.M.R. Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest. 2010, 28:885-895.
60. Hoppe G., Pennock M.A., Hoff HF.E.A. Oxidized low density lipoprotein-induced inhibition of processing of photoreceptor outer segments by RPE. Invest. Ophthalmol. Vis. Sci. 2001, 42:2714-2720.
61. Robbesyn F., Negre-Salvayre A.S.R. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic. Res. 2004, 38:541-551.
62. O'Leary D.P., Woolley B.L., Gough J.F., Wang D.R., Cotter J.H., Redmond HP.T.G. TLR-4 signalling accelerates colon cancer cell adhesion via NF-κB mediated transcriptional up-regulation of Nox-1. PLoS One 2012, 7:e44176.
63. Diebold I., Hess P.A., Görlach A.J. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol. Biol. Cell 2010, 21:2087-2096.
64. Pendyala S N.V. Redox regulation of Nox proteins. Respir. Physiol. Neurobiol. 2010, 174:265-271.
65. Pendyala S., Kalari M.J., Kleeberger S., Zhao S.R., Reddy Y., Garcia S.P., Natarajan V.J.G. Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: identification of functional antioxidant response elements on the Nox4 promoter. Free Radic. Biol. Med. 2011, 50:1749-1759.
66. Decanini A., Feng N.C., Ferrington X., Olsen TW.D.A. Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am. J. Ophthalmol. 2007, 143:607-615.
67. Bonello S., BelAiba Z.C., Djordjevic R.S., Hess T., Michiels J., Kietzmann C., Görlach A.T. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler. Thromb. Vasc. Biol. 2007, 27:755-761.
68. Cakir Y.B.S. Reactive species-mediated regulation of cell signaling and the cell cycle: the role of MAPK. Antioxid. Redox Signal 2005, 7:726-740.
69. Rossello X.S., Weisman I.U., Sun G.A., Wood WG.G.Y. AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes. Brain Res. 2012, 87-95.
70. Ma W., Guo L.S., Qu J., Hudson W., Schmidt B.I., Barile GR.A.M. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:1355-1361.
71. Zhao Z., Wang C.Y., Sternberg J., Freeman P., Grossniklaus M.L., Cai J.H.E. Age-related retinopathy in NRF2-deficient mice. PLoS One 2011, 6.
72. Rezaei K.A., Cai C.Y., Sternberg P.J. Modulation of Nrf2-dependent antioxidant functions in the RPE by Zip2, a zinc transporter protein. Invest. Ophthalmol. Vis. Sci. 2008, 49:1665-1670.
73. Bhattacharya S., Johnson C.E., Johnson LR.D.A. Age-related susceptibility to apoptosis in human retinal pigment epithelial cells is triggered by disruption of p53-Mdm2 association. Invest. Ophthalmol. Vis. Sci. 2012, 53:8350-8366.
74. Kwok A.K., Lai Y.C., Chan T.Y., Pang CP.K.P. Effects of trypan blue on cell viability and gene expression in human retinal pigment epithelial cells. Br. J. Ophthalmol. 2004, 88:1590-1594.
75. Nagineni C.N., William K.V., Detrick A., Hooks JJ.B. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J. Cell. Physiol. 2012, 227:116-126.
76. Smith G.W., Prentice D.C., Blanks J.H. The importance of hypoxia-regulated, RPE-targeted gene therapy for choroidal neovascularization. Adv. Exp. Med. Biol. 2012, 269-277.
77. Chen Y., Chen K.A., Yang P.Y. IL-17A stimulates the production of inflammatory mediators via Erk1/2, p38 MAPK, PI3K/Akt, and NF-κB pathways in ARPE-19 cells. Mol. Vis. 2011, 3072-3077.
78. Ping D., Rogers B.G., Boss J.M.E.M. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J. Immunol. 1999, 162:727-734.
79. Qiao X., Liu L.Y., Zhou X., Kelley T., Edwards M.R., Gao H.P. APE1/Ref-1 redox inhibitor APX3330 modulates choroidal endothelial cells by transcriptional regulation of NF-κB and STAT3 activity. Abstr. Assoc. Res. Vis. Ophthalmol. 2013, 274.
80. Mullins R.F., Skeie J.M.G.M. Glycoconjugates of choroidal neovascular membranes in age-related macular degeneration. Mol. Vis. 2005, 509-517.